Doc Logic, Absolutely. I think the “improved Direct” will blow people’s shorts off. The Phase 1 trial used a very conservative treatment regimen, as it was a novel tech: - Patients had multiple inoperable tumors, but only 1 tumor was injected with Direct - Only 6 injections (3 in first 2 wks and 3 at month 2, 4, and 8)
In the Phase 2 trials, they plan to: - Inject multiple inoperable tumors at each treatment visit, not just one. - Provide more frequent injections - Provide a larger total number of injections
Because the - number of Direct doses are not limited (leukapheresis is patient’s blood only) - as opposed to DCVax-L’s which is limited (by the available tumor resection) - a very large number of doses can be made in one manufacturing run - allowing for flexible dosing over extended periods - allows for a recurring treatment, a potential recurring revenue model
Market Data 
Markets 
AI
